Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
"We are very pleased to have Paul head up development of our key productcandidates as they move through late-stage clinical trials," statedChristopher J. Reinhard, Chief Executive Officer and Chairman of CardiumTherapeutics. "Paul's leadership and extensive clinical experience willgreatly assist us as we advance our Generx candidate now in Phase 3, andTissue Repair's Excellarate candidate, which is expected to complete its keyPhase 2 study this year."
Advertisement
Dr. Foster was previously Chief Medical Officer and Vice President ofClinical Development and Regulatory Affairs at Reata Pharmaceuticals. He hasheld leadership clinical development and medical affairs positions at IDECPharmaceuticals Corporation, Biogen Idec and Alpha Therapeutic and also hasexperience in the medical device arena, previously holding director positionsat Abbot Laboratories and Dade Behring. He is Board Certified in InternalMedicine and Hematology. He received his B.S. degree in Chemistry from theUniversity of Michigan, and his M.D. degree and medical training at DukeUniversity.
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc.and the Tissue Repair Company, are medical technology companies primarilyfocused on the development, manufacture and sale of innovative therapeuticproducts and devices for cardiovascular, ischemic and related indications.Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec,Ad5FGF4), is a DNA-based growth factor therapeutic being developed forpotential use by interventional cardiologists as a one-time treatment topromote and stimulate the growth of collateral circulation in the hearts ofpatients with ischemic conditions such as recurrent angina. For moreinformation about Cardium and its businesses, products and therapeuticcandidates, please visit http://www.cardiumthx.com or view its 2007 AnnualReport at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medicaltechnology company in the emerging field of patient temperature modulationtherapy to rapidly and controllably cool the body in order to reduce celldeath and damage following acute ischemic events such as cardiac arrest orstroke, and to potentially lessen or prevent associated injuries such asadverse neurological outcomes. For more information about Cardium's InnerCoolsubsidiary and patient temperature modulation, including InnerCool's CelsiusControl System(TM) and the CoolBlue(TM) System, please visithttp://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-basedbiopharmaceutical company focused on the development of growth factortherapeutics for the treatment of severe chronic diabetic wounds. TRC's leadproduct candidate, Excellarate(TM), is a DNA-activated c
